Systemic and localized scleroderma in children: Current and future treatment options

Pediatric Drugs

Volumn 8, Issue 2, 2006, Pages 85-97

  Rosenkranz, Margalit E ^a   Agle, Lucila M A ^a   Efthimiou, Petros ^a   Lehman, Thomas J A ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; BOSENTAN; CALCIUM ANTAGONIST; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; GLUCOCORTICOID; ILOPROST; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; METHOTREXATE; METHOXSALEN; NICARDIPINE; NIFEDIPINE; OMEPRAZOLE; PENICILLAMINE; PREDNISOLONE; PROSTACYCLIN; RECOMBINANT GAMMA INTERFERON; RELAXIN; THALIDOMIDE; UNINDEXED DRUG; UNIPROST; VASODILATOR AGENT; VERAPAMIL; VITAMIN D DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; ARTHRALGIA; B LYMPHOCYTE; CAUSE OF DEATH; CHILDHOOD MORTALITY; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CYTOPENIA; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EOSINOPHILIC FASCIITIS; ESOPHAGUS DISEASE; EXTRACORPOREAL PHOTOPHERESIS; GASTROESOPHAGEAL REFLUX; HEART; HEART DISEASE; HEMIFACIAL ATROPHY; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LINEAR SCLERODERMA; LIVER TOXICITY; LOCALIZED SCLERODERMA; LOW DRUG DOSE; LUNG; LUNG ALVEOLITIS; LUNG DISEASE; LUNG FIBROSIS; MORBIDITY; MORPHEA; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTIC SYNDROME; PATHOGENESIS; PEDIATRICS; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REMISSION; REVIEW; SKIN ATROPHY; SKIN BIOPSY; SKIN DEFECT; SKIN FIBROSIS; SKINFOLD; SURVIVAL RATE; SYMPATHECTOMY; SYNDROME CREST; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TELANGIECTASIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; ULTRAVIOLET IRRADIATION; UNSPECIFIED SIDE EFFECT;

CHILD; HUMANS; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SKIN;

EID: 33645839577     PISSN: 11745878     EISSN: 11745878     Source Type: Journal    
DOI: 10.2165/00148581-200608020-00002     Document Type: Review

References (154)

1. Doyle JA, Connolly SM, Winkelmann RK. Cutaneous and subcutaneous inflammatory sclerosis syndromes. Arch Dermatol 1982; 118 (11): 886-90
2. Preliminary criteria for the classification of systemic sclerosis (scleroderma): subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23 (5): 581-90
3. Belch JJ. The clinical assessment of the scleroderma spectrum disorders. Br Rheumatol 1993; 32 (5): 353-5
4. Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980; 69 (4): 520-6
5. Allen R. Overlap syndrome. In: Woo P, Ansell BM, editors. Pediatric rheumatology update. Oxford: Oxford University Press, 1990: 209-16
6. Cassidy JT, Petty RE. The systemic sclerodermas and related disorders. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. Philadelphia (PA): WB Saunders, 2001: 505-33
7. Uziel Y, Krafchik BR, Silverman ED, et al. Localized scleroderma in childhood: a report of 30 cases. Semin Arthritis Rheum 1994; 23 (5): 328-40
8. Vancheeswaran R, Black CM, David J, et al. Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum 1996; 39 (6): 1041-9
9. Blaszczyk M, Janniger CK, Jablonska S. Childhood scleroderma and its peculiarities. Cutis 1996; 58 (2): 141-4, 148-52
10. Jablonska S. Histopathology of linear scleroderma. In: Jablonska S, editor. Scleroderma and pseudoscleroderma. Warsaw: Warsaw Polish Medical Publishers: 1976: 191-233
11. Falanga V. Localized scleroderma. Med Clin North Am 1989; 73 (5): 1143-56
12. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70 (11): 1068-76
13. Lehman TJ. The Parry Romberg syndrome of progressive facial hemiatrophy and linear scleroderma en coup de sabre: mistaken diagnosis or overlapping conditions? J Rheumatol 1992; 19 (6): 844-5
14. Blaszczyk M, Jablonska S. Linear scleroderma en coup de sabre: relationship with progressive facial hemiatrophy (PFH). Adv Exp Med Biol 1999; 455: 101-4
15. Krafchik BR. Localized cutaneous scleroderma. Semin Dermatol 1992; 11 (1): 65-72
16. Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol 1980; 116 (2): 169-73
17. Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 1975; 88: 70-86
18. Rodnan GP, DiBartolomeo A, Medsger Jr TA. Proceedings: eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome. Arthritis Rheum 1975; 18 (5): 525
19. Uziel Y, Miller ML, Laxer RM. Scleroderma in children. Pediatr Clin North Am 1995; 42 (5): 1171-203
20. Steen VD, Oddis CV, Conte CG, et al. Incidence of systemic sclerosis in Allegheny County, Pennsylvania: a twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 1997; 40: 441-5
21. Cassidy JT, Sullivan DB, Dabich L, et al. Scleroderma in children. Arthritis Rheum 1977; 20 (2 Suppl.): 351-4
22. Denardo BA, Tucker LB, Miller LC, et al. Demography of a regional pediatric rheumatology patient population: affiliated children's arthritis centers of New England. J Rheumatol 1994; 21 (8): 1553-61
23. Foeldvari I. Results of a multi-national survey regarding a feasibility study for a therapeutic trial in juvenile systemic sclerosis [abstract]. Clin Exp Rheumatol 2000; 18 (3): 424
24. Sapadin AN, Esser AC, Fleischmajer R. Immunopathogenesis of scleroderma: evolving concepts. Mt Sinai J Med 2001; 68 (4-5): 233-42
25. Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977; 20 (4): 975-84
26. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996; 22 (4): 709-35
27. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma: the myth of the 'uninvolved skin'. Arthritis Rheum 1991; 34 (12): 1495-501
28. Albrecht HP, Hiller D, Hornstein OP, et al. Microcirculatory functions in systemic sclerosis: additional parameters for therapeutic concepts? J Invest Dermatol 1993; 101 (2): 211-5
29. Snowden N, Coupes B, Herrick A, et al. Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann Rheum Dis 1994; 53 (11): 763-7
30. Gruschwitz M, Muller PU, Sepp N, et al. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990; 94 (2): 197-203
31. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001; 13 (6): 505-11
32. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998; 338 (17): 1186-91
33. Foeldvari I, Zhavania M, Birdi N, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford) 2000; 39 (5): 556-9
34. Duffy CM, Laxer RM, Lee P, et al. Raynaud syndrome in childhood. J Pediatr 1989; 114 (1): 73-8
35. Spencer-Green G, Schlesinger M, Bove KE, et al. Nailfold capillary abnormalities in childhood rheumatic diseases. J Pediatr 1983; 102 (3): 341-6
36. Weber P, Ganser G, Frosch M, et al. Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. J Rheumatol 2000; 27 (11): 2692-5
37. Eid NS, Buchino JJ, Schikler KN. Pulmonary manifestations of rheumatic diseases. Pediatr Pulmonol Suppl 1999; 18: 91-2
38. Koh DM, Hansell DM. Computed tomography of diffuse interstitial lung disease in children. Clin Radiol 2000; 55 (9): 659-67
39. Seely JM, Jones LT, Wallace C, et al. Systemic sclerosis: using high-resolution CT to detect lung disease in children. AJR Am J Roentgenol 1998; 170 (3): 691-7
40. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37 (9): 1283-9
41. Suarez-Almazor ME, Catoggio LJ, Maldonado-Cocco JA, et al. Juvenile progressive systemic sclerosis: clinical and serologic findings. Arthritis Rheum 1985; 28 (6): 699-702
42. Quartier P, Bonnet D, Fournet JC, et al. Severe cardiac involvement in children with systemic sclerosis and myositis. J Rheumatol 2002; 29 (8): 1767-73
43. Follansbee WP, Curtiss EI, Medsger Jr TA, et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984; 310 (3): 142-8
44. Follansbee WP. The cardiovascular manifestations of systemic sclerosis (scleroderma). Curr Probl Cardiol 1986; 11 (5): 241-98
45. Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113 (5): 352-7
46. Beckett VL, Donadio Jr JV, Brennan Jr LA, et al. Use of captopril as early therapy for renal scleroderma: a prospective study. Mayo Clin Proc 1985; 60 (11): 763-71
47. Singsen BH. Scleroderma in childhood. Pediatr Clin North Am 1986; 33 (5): 1119-39
48. Rodnan GP, Medsger TA. The rheumatic manifestations of progressive systemic sclerosis (scleroderma). Clin Orthop 1968; 57: 81-93
49. Szymanska-Jagiello W, Rondio H, Jakubowska K. Changes in the locomotor system in progressive systemic sclerosis in children. Mater Med Pol 1972; 4 (4): 201-9
50. Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43 (11): 2437-44
51. Steen VD, Powell DL, Medsger Jr TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31 (2): 196-203
52. Kuwana M, Okano Y, Kaburaki J, et al. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994; 37 (6): 902-6
53. Catoggio LJ, Bernstein RM, Black CM, et al. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983; 42 (1): 23-7
54. Jacobsen S, Halberg P, Ullman S, et al. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol 1997; 16 (4): 384-90
55. Jacobsen S, Ullman S, Shen GQ, et al. Influence of clinical features, serum antinuclear antibodies, lung function on survival of patients with systemic sclerosis. J Rheumatol 2001; 28 (11): 2454-9
56. Sato S, Hamaguchi Y, Hasegawa M, et al. Clinical significance of anti-topoisomersase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford) 2001; 40 (10): 1135-40
57. Bernstein RM, Pereira RS, Holden AJ, et al. Autoantibodies in childhood scleroderma. Ann Rheum Dis 1985; 44 (8): 503-6
58. Rosenkranz M, Agle LA, Efthimiou P, et al. Is routine testing of anti-topoisomerase antibody (Scl-70) and anti-centromere antibody (ACA) warranted in a pediatric population [abstract]? Arthritis Rheum 2003; 48 (9 Suppl.): S1301
59. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002; 138 (1): 99-105
60. Steen VD, Medsger Jr TA, Rodnan GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982; 97 (5): 652-9
61. Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991; 18 (10): 1496-503
62. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42 (6): 1194-203
63. Medsger Jr TA, Lucas M, Wildy KS, et al. D-penicillamine in systemic sclerosis? Yes! Scand J Rheumatol 2001; 30 (4): 192-4
64. Furst DE, Clements PJ. D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol 2001; 30 (4): 189-91
65. Grassegger A, Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998; 139 (4): 639-48
66. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98 (12): 2739-45
67. Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132 (11): 871-9
68. Seibold JR. Relaxins: lessons and limitations. Curr Rheumatol Rep 2002; 4 (4): 275-6
69. van den Hoogen FH, van der Kraan PM, Boerbooms AM, et al. Effects of methotrexate on glycosaminoglycan production by scleroderma fibroblasts in culture. Ann Rheum Dis 1993; 52 (10): 758-61
70. van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35 (4): 364-72
71. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44 (6): 1351-8
72. Lehman TJ. Methotrexate for the treatment of early diffuse scleroderma: comment on the article by Pope, et al. [letter]. Arthritis Rheum 2002; 46 (3): 845
73. Foeldvari I, Lehman TJ. Is methotrexate a new perspective in the treatment of juvenile progressive systemic sclerosis [abstract]. Arthritis Rheum 1993; 36: S218
74. Foeldvari I. Scleroderma in children. Curr Opin Rheumatol 2002; 14 (6): 699-703
75. Degiannis D, Seibold JR, Czarnecki M, et al. Soluble interleukin-2 receptors in patients with systemic sclerosis: clinical and laboratory correlations. Arthritis Rheum 1990; 33 (3): 375-80
76. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35 (1): 67-72
77. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993; 36 (1): 75-83
78. Filaci G, Cutolo M, Basso M, et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) 2001; 40 (12): 1431-2
79. Helfrich DJ, Banner B, Steen VD, et al. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989; 32 (9): 1128-34
80. Steen VD, Medsger Jr TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41 (9): 1613-9
81. Schachna L, Wigley FM. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 2002; 14 (6): 686-93
82. Rodeheffer RJ, Rommer JA, Wigley F, et al. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983; 308 (15): 880-3
83. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42 (12): 2646-55
84. Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001; 108 (2): 241-50
85. Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19 (9): 1407-14
86. Scorza R, Caronni M, Mascagni B, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon: a randomized, controlled study. Clin Exp Rheumatol 2001; 19 (5): 503-8
87. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132 (12): 947-54
88. Akesson A. Cyclophosphamide therapy for scleroderma. Curr Opin Rheumatol 1998; 10 (6): 579-83
89. Steen VD, Lanz Jr JK, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 1994; 37 (9): 1290-6
90. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29 (4): 731-6
91. Pakas I, Ioannidis JP, Malagari K, et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29 (2): 298-304
92. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132 (6): 425-34
93. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (6): 800-4
94. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358 (9288): 1119-23
95. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (12): 896-903
96. Olive A, Maddison PJ, Davis M. Treatment of oesophagitis in scleroderma with omeprazole [letter]. Br J Rheumatol 1989; 28 (6): 553
97. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37 (9): 1265-82
98. Kahan A, Chaussade S, Gaudric M, et al. The effect of cisapride on gastrooesophageal dysfunction in systemic sclerosis: a controlled manometric study. Br J Clin Pharmacol 1991; 31 (6): 683-7
99. Folwaczny C, Laritz M, Meurer M, et al. Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma. Z Gastroenterol 1997; 35 (10): 905-12
100. Wang SJ, La JL, Chen DY, et al. Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 2002; 21 (1): 43-5
101. Kobayashi T, Kobayashi M, Naka M, et al. Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis. Intern Med 1993; 32 (7): 607-9
102. Kahn IJ, Jeffries GH, Sleisenger MH. Malabsorption in intestinal scleroderma: correction by antibiotics. N Engl J Med 1966; 274 (24): 1339-44
103. Kaye SA, Lim SG, Taylor M, et al. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol 1995; 34 (3): 265-9
104. Kahan A, Devaux JY, Amor B, et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986; 314 (22): 1397-402
105. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177 (6): 1675-80
106. Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000; 97 (2): 109-20
107. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92 (9): 3098-104
108. Martini A. Juvenile systemic scleroderma. Curr Rheumatol Rep 2001; 3 (5): 387-90
109. Furst DE. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 2002; 14 (3): 220-4
110. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60 (6): 577-84
111. Simms RW, Korn JH. Cytokine directed therapy in scleroderma: rationale, current status, the future. Curr Opin Rheumatol 2002; 14 (6): 717-22
112. McCormick LL, Zhang Y, Tootell E, et al. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999; 163 (10): 5693-9
113. Yamamoto T, Takagawa S, Katayama I, et al. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999; 92 (1): 6-13
114. Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, other fibrotic skin disorders. J Invest Dermatol 1996; 106 (4): 729-33
115. Gupta S, Clarkson MR, Duggan J, et al. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000; 58 (4): 1389-99
116. Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001; 44 (11): 2665-78
117. Ong C, Wong C, Roberts CR, et al. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998; 28 (9): 2619-29
118. Kodera T, McGaha TL, Phelps R, et al. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci U S A 2002; 99 (6): 3800-5
119. Peterson LS, Nelson AM, Su WP, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997; 24 (1): 73-80
120. Murray KJ, Laxer RM. Scleroderma in children and adolescents. Rheum Dis Clin North Am 2002; 28 (3): 603-24
121. Ghersetich I, Teofoli P, Benci M, et al. Localized scleroderma. Clin Dermatol 1994; 12 (2): 237-42
122. Krieg T, Braun-Falco O, Perlish JS, et al. Collagen synthesis in generalized morphea. Arch Dermatol Res 1983; 275 (6): 393-6
123. Torres JE, Sanchez JL. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol 1998; 20 (3): 242-5
124. Uziel Y, Krafchik BR, Feldman B, et al. Serum levels of soluble interleukin-2 receptor: a marker of disease activity in localized scleroderma. Arthritis Rheum 1994; 37 (6): 898-901
125. Ihn H, Sato S, Fujimoto M, et al. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995; 287 (2): 193-7
126. Kubo M, Ihn H, Yamane K, et al. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44 (3): 731-4
127. Rosenberg AM, Uziel Y, Krafchik BR, et al. Antinuclear antibodies in children with localized scleroderma. J Rheumatol 1995; 22 (12): 2337-43
128. Sato S, Ihn H, Soma Y, et al. Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993; 36 (8): 1137-41
129. Falanga V, Medsger TA, Reichlin M. High titers of antibodies to single-stranded DNA in linear scleroderma. Arch Dermatol 1985; 121 (3): 345-7
130. Hansen K, Serup J, Hoybye S. Antibodies to Borrelia burgdorferi and localised scleroderma [letter]. Lancet 1987; I (8534): 682
131. Nakashima T, Maeda M, Hayashi T, et al. A case of generalized morphea with a high titer of anti-Borrelia burgdorferi antibodies. J Dermatol 1999; 26 (12): 821-4
132. Ozkan S, Atabey N, Fetil E, et al. Evidence for Borrelia burgdorferi in morphea and lichen sclerosus. Int J Dermatol 2000; 39 (4): 278-83
133. Weide B, Schittek B, Klyscz T, et al. Morphoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesional skin by polymerase chain reaction. Br J Dermatol 2000; 143 (4): 780-5
134. Dillon WI, Saed GM, Fivenson DP. Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J Am Acad Dermatol 1995; 33 (4): 617-20
135. Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136 (1): 91-5
136. Guitart J, Greenberg M, Solomon LM. Localized scleroderma. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Baltimore (MD): Williams and Wilkins, 1996: 65-79
137. Mancuso G, Berdondini RM. Topical tacrolimus in the treatment of localized scleroderma. Eur J Dermatol 2003; 13 (6): 590-2
138. Lehman TJ. Systemic and localized scleroderma in children. Curr Opin Rheumatol 1996; 8 (6): 576-9
139. Foeldvari I. Progressive linear scleroderma and morphea in a child. J Pediatr 1998; 133 (2): 308
140. Seyger MM, van den Hoogen FH, de Boo T, et al. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998; 39 (2 Pt 1): 220-5
141. Fisher GJ, Kang S. Phototherapy for scleroderma: biologic rationale, results, promise. Curr Opin Rheumatol 2002; 14 (6): 723-6
142. Kerscher M, Dirschka T, Volkenandt M. Treatment of localised scleroderma by UVA1 phototherapy [letter]. Lancet 1995; 346 (8983): 1166
143. Gruss CJ, Von Kobyletzki G, Behrens-Williams SC, et al. Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed 2001; 17 (4): 149-55
144. Kerscher M, Volkenandt M, Gruss C, et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998; 38 (1): 21-6
145. Stege H, Berneburg M, Humke S, et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997; 36 (6 Pt 1): 938-44
146. Scharffetter-Kochanek K, Goldermann R, Lehmann P, et al. PUVA therapy in disabling pansclerotic morphoea of children. Br J Dermatol 1995; 132 (5): 830-1
147. Kreuter A, Gambichler T, Avermaete A, et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 2001; 18 (3): 241-5
148. Hulshof MM, Pavel S, Breedveld FC, et al. Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994; 130 (10): 1290-3
149. Hulshof MM, Bouwes Bavinck JN, Bergman W, et al. Double-blind, placebocontrolled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000; 43 (6): 1017-23
150. Elst EF, Van Suijlekom-Smit LW, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 1999; 16 (1): 53-8
151. Kesler RW, McDonald TD, Balasubramaniam M, et al. Linear scleroderma in children. Am J Dis Child 1981; 135 (8): 738-40
152. Moynahan EJ. D(-)penicillamine in morphoea (localised scleroderma). Lancet 1973; I (7800): 428-9
153. Moynahan EJ. Penicillamine in the treatment of morphoea and keloid in children. Postgrad Med J 1974; 50 Suppl. 2: 39-41
154. Falanga V, Medsger Jr TA. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990; 126 (5): 609-12